In the Ph+ ALL subsets, TKIs such as imatinib or dasatinib directly targeting the BCR-ABL fusion oncogene are essential for a successful therapy [89, 73, 83, 90]. Here, ABL1 is linked to acute lymphoblastic leukemia.